Non-small cell lung cancer+4
RecruitingStudy on the Effects of Adding Durvalumab After Chemotherapy and Surgery in Patients with Resectable Non-Small Cell Lung Cancer
Study on the Effects of Adding Durvalumab After Chemotherapy and Surgery in Patients with Resectable Non-Small Cell Lung Cancer
- Disease:Non-small cell lung cancerNon-small cell lung cancer stage III+3
- Substances:CarboplatinCisplatin+4
Ireland- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:ETOP IBCSG Partners Foundation
















